LADX
LadRx Corporation
Price Chart
Latest Quote
$0.10
+0.00 (+0.00%)
Current Price
| Previous Close | $0.10 |
| Open | $0.11 |
| Day High | $0.11 |
| Day Low | $0.11 |
| Volume | 10 |
Stock Information
| Shares Outstanding | 495K |
| Cash Equivalents | $207K |
| Net Income | $-2.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $50K |
| EPS (TTM) | $-5.04 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-202K |
| Income | $-2.50M |
| Book/sh | $-4.31 |
| Cash/sh | $0.42 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 0.09 |
| Current Ratio | 0.11 |
Returns & Margins
| ROA | -176.87% |
Ownership
| Insider Ownership | 1.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 1.37 |
| P/B | -0.02 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.07 |
| SMA50 | $0.08 |
| SMA200 | $0.29 |
| ATR | 0.0071 |
| Shares Float | 492K |
| Short Float | 0.77% |
| Short Ratio | 1.04 |
| Volatility | 1.24 |
Performance History
| Week | -90.91% |
| Month | -80.00% |
| Quarter | -80.00% |
| 6 Months | -91.67% |
| YTD | +0.00% |
| Year | -99.33% |
| 3 Years | -99.78% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.01 | 0 |
| 2026-06-23 | $0.01 | 0 |
| 2026-06-22 | $0.01 | 400 |
| 2026-06-18 | $0.11 | 0 |
| 2026-06-17 | $0.11 | 0 |
| 2026-06-16 | $0.11 | 0 |
| 2026-06-15 | $0.11 | 0 |
| 2026-06-12 | $0.11 | 0 |
| 2026-06-11 | $0.11 | 0 |
| 2026-06-10 | $0.11 | 0 |
| 2026-06-09 | $0.11 | 0 |
| 2026-06-08 | $0.11 | 0 |
| 2026-06-05 | $0.11 | 0 |
| 2026-06-04 | $0.11 | 0 |
| 2026-06-03 | $0.11 | 200 |
| 2026-06-02 | $0.01 | 0 |
| 2026-06-01 | $0.01 | 0 |
| 2026-05-29 | $0.01 | 200 |
| 2026-05-28 | $0.05 | 0 |
| 2026-05-27 | $0.05 | 0 |
| 2026-05-26 | $0.05 | 0 |
About LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on LADX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $3,623,414 | $3,823,324 | $4,560,004 | $5,979,978 |
| Other Income Expense | $2,000,000 | $4,168,635 | $348,626 | $-7,213,092 |
| Net Non Operating Interest Income Expense | $33,457 | $55,434 | $11,689 | $16,822 |
| Operating Expense | $3,623,414 | $3,823,324 | $4,560,004 | $5,979,978 |
| General And Administrative Expense | $2,845,000 | $3,532,000 | $4,545,000 | $5,966,000 |
| Other Non Operating Income Expenses | - | $1,416 | $-2,615 | $-7,213,092 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,589,685 | $400,443 | $-4,200,573 | $-13,176,663 |
| Net Interest Income | $33,457 | $55,434 | $11,689 | $16,822 |
| Interest Income | $33,457 | $55,434 | $11,689 | $16,822 |
| Normalized Income | $-3,589,685 | $-2,891,660 | $-4,551,814 | $-13,176,663 |
| Net Income From Continuing And Discontinued Operation | $-1,589,685 | $400,443 | $-4,200,573 | $-13,176,663 |
| Total Operating Income As Reported | $-3,623,142 | $-3,823,626 | $-4,560,888 | $-12,076,990 |
| Net Income Common Stockholders | $-1,589,685 | $331,634 | $-4,761,954 | $-13,348,331 |
| Net Income | $-1,589,685 | $400,443 | $-4,200,573 | $-13,176,663 |
| Net Income Including Noncontrolling Interests | $-1,589,685 | $400,443 | $-4,199,689 | $-13,176,663 |
| Net Income Continuous Operations | $-1,589,685 | $400,443 | $-4,199,689 | $-13,176,663 |
| Pretax Income | $-1,589,685 | $400,443 | $-4,199,689 | $-13,176,248 |
| Special Income Charges | $2,000,000 | $4,167,219 | $351,241 | $0 |
| Interest Income Non Operating | $33,457 | $55,434 | $11,689 | $16,822 |
| Operating Income | $-3,623,414 | $-3,823,324 | $-4,560,004 | $-5,979,978 |
| Depreciation Amortization Depletion Income Statement | $5,712 | $11,835 | $15,004 | $13,978 |
| Depreciation And Amortization In Income Statement | $5,712 | $11,835 | $15,004 | $13,978 |
| Per Share | ||||
| Diluted EPS | $-3.21 | $0.68 | $-0.11 | $-35.00 |
| Basic EPS | $-3.21 | $0.68 | $-0.11 | $-35.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $875,116 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,617,702 | $-7,978,708 | $-4,896,241 | $-5,966,000 |
| Total Unusual Items | $2,000,000 | $4,167,219 | $351,241 | $0 |
| Total Unusual Items Excluding Goodwill | $2,000,000 | $4,167,219 | $351,241 | $0 |
| Reconciled Depreciation | $5,712 | $11,834 | $15,004 | $13,978 |
| EBITDA (Bullshit earnings) | $-3,617,702 | $-3,811,489 | $-4,545,000 | $-5,966,000 |
| EBIT | $-3,623,414 | $-3,823,324 | $-4,560,004 | $-5,979,978 |
| Diluted Average Shares | $495,092 | $488,392 | $450,374 | $375,846 |
| Basic Average Shares | $495,092 | $488,392 | $450,374 | $375,846 |
| Diluted NI Availto Com Stockholders | $-1,589,685 | $331,634 | $-4,761,954 | $-13,348,331 |
| Gain On Sale Of Ppe | $2,000,000 | $4,167,219 | $0 | - |
| Research And Development | $772,702 | $279,489 | $0 | $0 |
| Selling General And Administration | $2,845,000 | $3,532,000 | $4,545,000 | $5,966,000 |
| Other Gand A | $2,782,000 | $3,532,000 | $4,534,000 | $5,966,000 |
| Salaries And Wages | $63,000 | $0 | $11,000 | $0 |
| Preferred Stock Dividends | - | $68,809 | $561,381 | $171,668 |
| Other Special Charges | - | - | $-351,241 | - |
| Tax Provision | - | - | - | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,419,429 | $107,354 | $25,720 | $4,776,419 |
| Total Assets | $839,512 | $2,307,882 | $2,246,772 | $8,726,777 |
| Total Non Current Assets | $2,474 | $46,024 | $243,035 | $446,792 |
| Other Non Current Assets | $1,475 | $7,703 | $7,703 | $16,836 |
| Current Assets | $837,038 | $2,261,858 | $2,003,737 | $8,279,985 |
| Other Current Assets | $77,296 | $191,783 | $628,745 | $1,310,382 |
| Cash Cash Equivalents And Short Term Investments | $759,742 | $2,070,075 | $1,374,992 | $6,769,603 |
| Cash And Cash Equivalents | $759,742 | $2,070,075 | $1,374,992 | $6,769,603 |
| Receivables | - | - | $0 | $200,000 |
| Accounts Receivable | - | - | $0 | $200,000 |
| Cash Financial | - | - | $1,374,992 | $6,769,603 |
| Prepaid Assets | - | - | - | $1,310,382 |
| Debt | ||||
| Total Debt | $0 | $33,606 | $229,607 | $415,200 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $33,526 | $216,381 |
| Current Debt And Capital Lease Obligation | - | $33,606 | $196,081 | $198,819 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,258,941 | $2,200,528 | $2,221,052 | $3,950,358 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $33,526 | $216,381 |
| Current Liabilities | $2,258,941 | $2,200,528 | $2,187,526 | $3,733,977 |
| Other Current Liabilities | $120,898 | $13,269 | $18,380 | $7,263 |
| Payables And Accrued Expenses | $2,138,043 | $2,153,653 | $1,973,065 | $3,527,895 |
| Payables | $1,056,662 | $1,202,689 | $975,944 | $1,726,767 |
| Accounts Payable | $1,056,662 | $1,202,689 | $975,944 | $1,470,652 |
| Other Payable | - | - | $50,191 | $256,115 |
| Equity | ||||
| Common Stock Equity | $-1,419,429 | $107,354 | $-1,317,964 | $753,719 |
| Total Equity Gross Minority Interest | $-1,419,429 | $107,354 | $25,720 | $4,776,419 |
| Stockholders Equity | $-1,419,429 | $107,354 | $25,720 | $4,776,419 |
| Retained Earnings | $-490,095,716 | $-488,506,031 | $-488,837,665 | $-484,075,711 |
| Preferred Stock Equity | - | - | $1,343,684 | $4,022,700 |
| Other | ||||
| Ordinary Shares Number | $495,092 | $495,092 | $450,373 | $387,800 |
| Share Issued | $495,092 | $495,092 | $450,373 | $387,800 |
| Tangible Book Value | $-1,419,429 | $107,354 | $-1,317,964 | $753,719 |
| Invested Capital | $-1,419,429 | $107,354 | $-1,317,964 | $753,719 |
| Working Capital | $-1,421,903 | $61,330 | $-183,789 | $4,546,008 |
| Capital Lease Obligations | $0 | $33,606 | $229,607 | $415,200 |
| Total Capitalization | $-1,419,429 | $107,354 | $25,720 | $4,776,419 |
| Additional Paid In Capital | $488,675,792 | $488,612,890 | $487,519,251 | $484,790,650 |
| Capital Stock | $495 | $495 | $1,344,134 | $4,061,480 |
| Common Stock | $495 | $495 | $450 | $38,780 |
| Preferred Stock | $0 | $0 | $1,343,684 | $4,022,700 |
| Current Capital Lease Obligation | $0 | $33,606 | $196,081 | $198,819 |
| Current Accrued Expenses | $1,081,381 | $950,964 | $997,121 | $1,801,128 |
| Net PPE | $999 | $38,321 | $235,332 | $429,956 |
| Accumulated Depreciation | $-17,688 | $-42,031 | $-30,196 | $-26,944 |
| Gross PPE | $18,687 | $80,352 | $265,528 | $456,900 |
| Other Properties | $18,687 | $80,352 | $265,528 | $456,900 |
| Long Term Capital Lease Obligation | - | $0 | $33,526 | $216,381 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,310,333 | $1,013,892 | $-4,833,230 | $-12,315,894 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,310,333 | $1,013,892 | $-4,832,464 | $-12,308,890 |
| Cash Flow From Continuing Operating Activities | $-1,310,333 | $1,013,892 | $-4,832,544 | $-12,308,890 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $-766 | $-7,004 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-766 | $-7,004 |
| Capital Expenditure | - | - | $-766 | $-7,004 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-250,000 | $0 | - |
| Financing Cash Flow | $0 | $-318,809 | $-561,381 | $9,082,122 |
| Cash Flow From Continuing Financing Activities | $0 | $-318,809 | $-561,381 | $9,082,122 |
| Cash Dividends Paid | $0 | $-68,809 | $-561,381 | $-171,668 |
| Preferred Stock Dividend Paid | $0 | $-68,809 | $-561,381 | $-171,668 |
| Net Common Stock Issuance | $0 | $-250,000 | $0 | $9,175,790 |
| Issuance Of Capital Stock | - | - | $0 | $9,175,790 |
| Common Stock Issuance | - | - | $0 | $9,175,790 |
| Other | ||||
| End Cash Position | $759,742 | $2,070,075 | $1,374,992 | $6,769,603 |
| Beginning Cash Position | $2,070,075 | $1,374,992 | $6,769,603 | $10,003,375 |
| Changes In Cash | $-1,310,333 | $695,083 | $-5,394,611 | $-3,233,772 |
| Common Stock Payments | $0 | $-250,000 | $0 | - |
| Change In Working Capital | $210,738 | $601,615 | $-658,230 | $853,795 |
| Change In Other Current Liabilities | $-33,606 | $-196,002 | $-185,593 | $-181,103 |
| Change In Other Current Assets | $37,838 | $185,176 | $189,439 | $183,306 |
| Change In Payables And Accrued Expense | $92,019 | $175,480 | $-1,543,713 | $942,194 |
| Change In Accrued Expense | $238,046 | $-51,265 | $-1,049,005 | $873,596 |
| Change In Payable | $-146,027 | $226,745 | $-494,708 | $68,598 |
| Change In Account Payable | $-146,027 | $226,745 | $-494,708 | $68,598 |
| Change In Prepaid Assets | $114,487 | $436,961 | $681,637 | $-215,707 |
| Stock Based Compensation | $62,902 | $0 | $11,255 | $0 |
| Depreciation Amortization Depletion | $5,712 | $11,834 | $15,004 | $13,978 |
| Depreciation And Amortization | $5,712 | $11,834 | $15,004 | $13,978 |
| Net Income From Continuing Operations | $-1,589,685 | $400,443 | $-4,200,573 | $-13,176,663 |
| Net PPE Purchase And Sale | - | $0 | $-766 | $-7,004 |
| Purchase Of PPE | - | $0 | $-766 | $-7,004 |
| Change In Receivables | - | $0 | $200,000 | $125,105 |
| Depreciation | - | $11,834 | $15,004 | - |
| Proceeds From Stock Option Exercised | - | - | $0 | $78,000 |
| Other Non Cash Items | - | - | $80 | - |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-02-02